Biotechnology company Solu Therapeutics announced on Tuesday the appointment of Sergio Santillana, MD, MSc, MBA, as its new chief medical officer.
In this role Dr Santillana will manage strategic direction and execution in the company's clinical development programmes, leading its efforts and teams in clinical operations, clinical research, regulatory affairs, pharmacovigilance, biometrics and medical affairs. He will also help shape Solu's long-term R&D strategy, guiding the transition of early-stage discoveries into clinical-stage programmes, and developing these programmes across all phases of drug development.
Dr Santillana has more than 30 years of clinical experience and over 20 years working to develop novel oncology therapies, which includes small molecules, monoclonal antibodies and bispecific antibodies. He has served as chief medical officer at Ikena Oncology, Merrimack Pharmaceuticals and Ariad Pharmaceuticals, and held several leadership roles at Eli Lilly, GlaxoSmithKline and Takeda Pharmaceuticals.
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Carisma and Moderna expand collaboration
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024
Cantargia reports promising data for nadunolimab in cancer treatment